Literature DB >> 18656518

The contribution of type I interferon signaling to immunity induced by alphavirus replicon vaccines.

Joseph M Thompson1, Alan C Whitmore, Herman F Staats, Robert Johnston.   

Abstract

The type I interferon (IFN) system is critical for protecting the mammalian host from numerous virus infections and plays a key role in shaping the antiviral adaptive immune response. In this report, the importance of type I IFN signaling was assessed in a mouse model of alphavirus-induced humoral immune induction. Venezuelan equine encephalitis virus replicon particles (VRP) expressing the hemagglutinin (HA) gene from influenza virus (HA-VRP) were used to vaccinate both wildtype (wt) and IFN alpha/beta receptor knockout (RKO) mice. HA-VRP vaccination induced equivalent levels of flu-specific systemic IgG, mucosal IgG, and systemic IgA antibodies in both wt and IFN RKO mice. In contrast, HA-VRP vaccination of IFN RKO mice failed to induce significant levels of flu-specific mucosal IgA antibodies at multiple mucosal surfaces. In the VRP adjuvant system, co-delivery of null VRP with ovalbumin (OVA) protein significantly increased the levels of OVA-specific serum IgG, fecal IgG, and fecal IgA antibodies in both wt and RKO mice, suggesting that type I IFN signaling plays a less significant role in the VRP adjuvant effect. Taken together, these results suggest that (1) at least in regard to IFN signaling, the mechanisms which regulate alphavirus-induced immunity differ when VRP are utilized as expression vectors as opposed to adjuvants, and (2) type I IFN signaling is required for the induction of mucosal IgA antibodies directed against VRP-expressed antigen. These results shed new light on the regulatory networks which promote immune induction, and specifically mucosal immune induction, with alphavirus vaccine vectors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18656518      PMCID: PMC3595171          DOI: 10.1016/j.vaccine.2008.07.011

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  33 in total

1.  Virus interference. I. The interferon.

Authors:  A ISAACS; J LINDENMANN
Journal:  Proc R Soc Lond B Biol Sci       Date:  1957-09-12

Review 2.  Type I interferons in host defense.

Authors:  Daniel B Stetson; Ruslan Medzhitov
Journal:  Immunity       Date:  2006-09       Impact factor: 31.745

3.  Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level.

Authors:  Laura Bracci; Irene Canini; Simona Puzelli; Paola Sestili; Massimo Venditti; Massimo Spada; Isabella Donatelli; Filippo Belardelli; Enrico Proietti
Journal:  Vaccine       Date:  2005-04-27       Impact factor: 3.641

Review 4.  How cells respond to interferons.

Authors:  G R Stark; I M Kerr; B R Williams; R H Silverman; R D Schreiber
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

Review 5.  Natural killer cells in antiviral defense: function and regulation by innate cytokines.

Authors:  C A Biron; K B Nguyen; G C Pien; L P Cousens; T P Salazar-Mather
Journal:  Annu Rev Immunol       Date:  1999       Impact factor: 28.527

6.  A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons alpha and beta and alters macrophage responses.

Authors:  S Y Hwang; P J Hertzog; K A Holland; S H Sumarsono; M J Tymms; J A Hamilton; G Whitty; I Bertoncello; I Kola
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

7.  Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo.

Authors:  P Pushko; M Parker; G V Ludwig; N L Davis; R E Johnston; J F Smith
Journal:  Virology       Date:  1997-12-22       Impact factor: 3.616

Review 8.  Role of early cytokines, including alpha and beta interferons (IFN-alpha/beta), in innate and adaptive immune responses to viral infections.

Authors:  C A Biron
Journal:  Semin Immunol       Date:  1998-10       Impact factor: 11.130

Review 9.  Immune defence in mice lacking type I and/or type II interferon receptors.

Authors:  M F van den Broek; U Müller; S Huang; R M Zinkernagel; M Aguet
Journal:  Immunol Rev       Date:  1995-12       Impact factor: 12.988

10.  Functional role of type I and type II interferons in antiviral defense.

Authors:  U Müller; U Steinhoff; L F Reis; S Hemmi; J Pavlovic; R M Zinkernagel; M Aguet
Journal:  Science       Date:  1994-06-24       Impact factor: 47.728

View more
  13 in total

1.  A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge.

Authors:  Meagan Bolles; Damon Deming; Kristin Long; Sudhakar Agnihothram; Alan Whitmore; Martin Ferris; William Funkhouser; Lisa Gralinski; Allison Totura; Mark Heise; Ralph S Baric
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

2.  Infected dendritic cells are sufficient to mediate the adjuvant activity generated by Venezuelan equine encephalitis virus replicon particles.

Authors:  Daniel R Tonkin; Alan Whitmore; Robert E Johnston; Mario Barro
Journal:  Vaccine       Date:  2012-04-21       Impact factor: 3.641

3.  Design of chimeric alphaviruses with a programmed, attenuated, cell type-restricted phenotype.

Authors:  Dal Young Kim; Svetlana Atasheva; Niall J Foy; Eryu Wang; Elena I Frolova; Scott Weaver; Ilya Frolov
Journal:  J Virol       Date:  2011-02-23       Impact factor: 5.103

4.  A mucosal adjuvant for the inactivated poliovirus vaccine.

Authors:  Benjamin P Steil; Patricia Jorquera; Janny Westdijk; Wilfried A M Bakker; Robert E Johnston; Mario Barro
Journal:  Vaccine       Date:  2013-12-13       Impact factor: 3.641

5.  Alphavirus replicon-based adjuvants enhance the immunogenicity and effectiveness of Fluzone ® in rhesus macaques.

Authors:  Timothy D Carroll; Shannon R Matzinger; Mario Barro; Linda Fritts; Michael B McChesney; Christopher J Miller; Robert E Johnston
Journal:  Vaccine       Date:  2010-11-25       Impact factor: 3.641

6.  A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measles.

Authors:  Chien-Hsiung Pan; Catherine E Greer; Debra Hauer; Harold S Legg; Eun-Young Lee; M Jeff Bergen; Brandyn Lau; Robert J Adams; John M Polo; Diane E Griffin
Journal:  J Virol       Date:  2010-02-03       Impact factor: 5.103

7.  Comparison of the immune responses induced by chimeric alphavirus-vectored and formalin-inactivated alum-precipitated measles vaccines in mice.

Authors:  M Jeff Bergen; Chien-Hsiung Pan; Catherine E Greer; Harold S Legg; John M Polo; Diane E Griffin
Journal:  PLoS One       Date:  2010-04-22       Impact factor: 3.240

8.  Immunogenicity and efficacy of alphavirus-derived replicon vaccines for respiratory syncytial virus and human metapneumovirus in nonhuman primates.

Authors:  John T Bates; Jennifer A Pickens; Jennifer E Schuster; Monika Johnson; Sharon J Tollefson; John V Williams; Nancy L Davis; Robert E Johnston; Nancy Schultz-Darken; James C Slaughter; Frances Smith-House; James E Crowe
Journal:  Vaccine       Date:  2016-01-07       Impact factor: 3.641

9.  An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal mice.

Authors:  Syed Muaz Khalil; Daniel R Tonkin; Andrew T Snead; Griffith D Parks; Robert E Johnston; Laura J White
Journal:  J Virol       Date:  2014-06-04       Impact factor: 5.103

10.  The adjuvant activity of alphavirus replicons is enhanced by incorporating the microbial molecule flagellin into the replicon.

Authors:  Maria L Knudsen; Daniel X Johansson; Linda Kostic; Eva K L Nordström; Karin Tegerstedt; Anna Pasetto; Steven E Applequist; Karl Ljungberg; Jean-Claude Sirard; Peter Liljeström
Journal:  PLoS One       Date:  2013-06-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.